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Abstract: Roughly 50% or more of the word population suffer from a form of periodontitis and about
750 million people suffer from a severe form (1). This number is higher than, for example, diabetes,
which affects around 450 million adult patients (2). According to an estimate of WHO in 2018, the total
number of people living within 5 years of cancer diagnosis, the so-called 5-year prevalence, is estimated
at 43.8 million (3). In view of these figures, periodontitis is indeed an important topic. Especially if
one considers the clinical connections with diabetes or other systemic diseases (4, 5). The prevention
and therapy of this inflammatory disease, which is mostly caused by bacteria, must be intensified and
intensively fought from a health policy perspective.
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PERIODONTAL RESEARCH: THE CORNERSTONE OF HEALTH
Roughly 50% or more of the word population suffer from a form of periodontitis and about 750
million people suffer from a severe form (1). This number is higher than, for example, diabetes,
which affects around 450 million adult patients (2). According to an estimate of WHO in 2018, the
total number of people living within 5 years of cancer diagnosis, the so-called 5-year prevalence, is
estimated at 43.8 million (3). In view of these figures, periodontitis is indeed an important topic.
Especially if one considers the clinical connections with diabetes or other systemic diseases (4, 5).
The prevention and therapy of this inflammatory disease, which is mostly caused by bacteria, must
be intensified and intensively fought from a health policy perspective.
“BIO”
“BIO” and stands for the Greek word βioç “Life” and has received an important meaning in
language and life and is far more than a powerful word stem. A healthy lifestyle is more than ever
in demand and on everyone’s lips. The latter actually also contains a large mass of “bio”—especially
in the form of biofilms.
A sterile oral cavity would probably not be realistic and probably not even desired by nature.
There are good reasons to socialize humans and other animals with a variety of bacteria and, above
all, to colonize mucous membranes and skin in a targeted manner. While there is no doubt that a
healthy microbiome is necessary for the intestine to be able to “go about its daily business,” many
people wonder why we have an oral flora (6).
What is certain is that bacteria are numerically superior to host cells and have been with us for
a long time in both good and bad times: Microbiological studies on tartar from different periods of
human history prove this: The diversity of bacteria in humans has always been large and already in
the Stone Age it was very diversified among hunters and gatherers. However, paropathogenic germs
such as P. gingivalis were not yet detectable. Above all, social “revolutions” such as those during the
Neolithic or industrialization periods led to bacterial upheavals—not only in a positive sense—in
the carrier and its microbiological load and thus to pathological leaps in development (caries and
periodontitis) (7).
BIO-FILM
Biofilms belong to us and to the oral ecosystem (8). This seems to be the state of error—to be
clear. But “healthy” it must be, i.e., symbiotic. Let’s take the Koala as an example. Especially with
these cute balls of wool, the intestines play an important role. It is specific bacteria that enable the
digestion of eucalyptus leaves. If the intestinal flora is disturbed, the nutritional basis and existence
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of these animals is severely disturbed (9). This happens, for
example, after chlamydia infections. These are treated with
antibiotics and Lonepinella koalarum, a bacterium that plays an
important role in digestion (tannin degradation), is also affected.
Alternative treatments are therefore urgently sought in order not
to endanger the populations. Stool transplants have already been
mentioned and carried out as an option.
Concepts are therefore in demand which not only reduce
but also modify pathogenic biofilms and allow a permanent
biological balance with the host. The “Guided Biofilm Therapy”
represents an approach and slogan that has already been used
by the industry in this context with airpolishing. However,
if one thinks a bit further and refers to the underlying
terminology (GBR/GTR), one should perhaps rather speak of
“Guided Biofilm Regeneration.” According to this, not only
the mechanical cleaning but also the repopulation could be
conceptually “controlled.”
DIAGNOSTICS AND ECOLOGIC BALANCE
Adequate diagnostics is also a basic prerequisite. The actual
periodontal classification provides for patient-oriented point-
of-care diagnostics and in the future, tests immunological,
and microbiological approaches including monitoring should
be increasingly considered (10). Finally, probiotics, anti-
inflammatory, and possibly dietary considerations are of interest
in the context of controlled re-colonization in order to modify
the pocket environment (11). In short—biofilm management
will probably not only pursue mechanistic considerations in
the future, but will also increasingly take into account the
establishment of a healthy oral flora on an interdisciplinary basis.
Perhaps we will soon experience a symbiotic “revolution” or
co-evolution in this context. While after the initial euphoria
in the post-war antibiotics era statements such as “Almost
all experts agree that viral and bacterial infections will be
eradicated by the year 2000” (Time Magazine, February 25,
1966), today it seems that the evidence is changing and new
challenges have developed. The future of cause-related therapy
will be challenged . . . .
WHERE ARE WE TODAY—WHERE DO WE
GO?
If we look where we stand today, various critical remarks remain.
For example, periodontitis remains undetected or misdiagnosed
in too many cases, and treatment, even in the 21st century,
is still mainly based on direct cause-related strategies, which
are based on influencing the pathological agent(s), for example
by removing hard and soft bacterial deposits, but the host
and related immunologic factors are not routinely considered
yet in the routine treatment regimen, with few exceptions
maybe. Undoubtedly, a plethora of new studies including
different clinical approaches and materials are published every
month, very few of them really find their way into daily
practice. Mostly, monotherapies are examined. Unfortunately,
combination strategies often receive too little attention. This is
probably also due to the fact that it is difficult to prove the most
effective treatment steps for a complex topic such as periodontitis
and the many influencing factors anyhow.
GATHERING NEW KNOWLEDGE—A
DIFFICULT TASK
Attempts to summarize the available evidence in systematic
reviews and to publish generally valid decision-making aids
are also well-intentioned, but if one is critical and honest, the
available evidence remains unfortunately often inadequate and
based on a few studies only, some of which are of low quality
(12). Therefore, the sad conclusion is practically always the
same and unanimous that further well-conducted studies are
necessary to draw definitive conclusions... This is not meant
as criticism. We all know how complex, expensive and lengthy
clinical studies are. Therefore, an important aspect in the future
must be the comparability and standardization of clinical studies.
And research should be coordinated and harmonized: Experts
should not only meet to discuss existing evidence, but also to
prospectively discuss research efforts. Importantly, the evaluation
of the efficacy and efficiency of treatment modalities mostly
measures differences. But the individual patient does not need
respective statistical estimates, but clear clinical parameters and
reference values (13). What does a difference of one millimeter
or 12 percent really mean in most contexts? For whether an
intervention is successful or not is not always manifested in a
measured difference to a control treatment or even gold standard,
but is expressed in the individual achievement of success or
failure parameters. Future studies and reviews should also focus
on this.
LET US WORK …
While many journals are filled with outstanding and interesting
laboratory and pre-clinical studies also at amolecular level, which
investigate the understanding of various biological processes,
they unfortunately often have only limited clinical relevance and
will never be implemented in a clinical context. Although the
aim of “Frontiers in Dentistry” and the Section Periodontics
is to cross boundaries in the field and discover new things,
the focus should always be on clinically applicable issues and a
clear focus should be based on a corresponding hypothesis from
which our patients can benefit in one way or another—sooner
or later. Frontiers in Dentistry, invites researchers to submit
their innovative work and contribute to the improvement of
periodontal and systemic health.
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